EZH2-IN-13

• Description:

  EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity[1].

• UNSPSC:

  12352005

• Target:

  Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ezh2-in-13.html

• Concentration:

  10mM

• Purity:

  99.72

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(C2=CC=C(CN3CCNCC3)C=C2)=CC(N(C4CCOCC4)CC)=C1C)NCC5=C(C)C=C(C)NC5=O

• Molecular Formula:

  C34H45N5O3

• Molecular Weight:

  571.75

• References & Citations:

  [1]Jesse Smith, et al. Methods of treating cancer. WO2017139404.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1403255-41-3]